Evidence map›Paper›PMID 41896453›Full record

ArticleCommunications biology2026

Engineering a dimeric single-domain antibody for improved detection and neutralization of amyloid-β oligomers.

Liliana Napolitano, Devkee M Vadukul, Alessandra Bigi, Pasquale Palladino, Cristina Cecchi, Fabrizio Chiti, Roberta Cascella, Francesco A Aprile

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liliana NapolitanoDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.
Devkee M VadukulDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK.
Alessandra BigiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-1067-6288
Pasquale PalladinoDipartimento di Chimica 'Ugo Schiff'-DICUS, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-3869-5085
Cristina CecchiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0001-8387-7737
Fabrizio ChitiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.
Roberta CascellaDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy. roberta.cascella@unifi.it.ORCID http://orcid.org/0000-0001-9856-6843
Francesco A AprileDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK. f.aprile@imperial.ac.uk.ORCID http://orcid.org/0000-0002-5040-4420

Funding

Alzheimer's Research UK (ARUK) ARUK-PG2019B-020Regione Toscana (Tuscany Region) Progetto PramaUniversità degli Studi di Firenze (University of Florence) Fondi Ateneo
6 · The paper itself

Abstract

Soluble Aβ oligomers are regarded as major neurotoxic agents in Alzheimer's disease. Several monoclonal antibodies have been developed to target Aβ oligomers, but most of them show limited specificity binding also to monomers and fibrils. To generate an antibody with high specificity for the oligomers, we aimed to increase the efficiency and sensitivity of a human VH-derived Aβ-oligomer-specific single domain antibody, called DesAb-O. We engineered a dimeric DesAb-O variant, DiDesAb-O, which showed significantly higher binding affinity for Aβ oligomers as compared to the monomeric sdAb. DiDesAb-O selectively detected Aβ

Indexed as

Amyloid beta-PeptidesAntibodies, NeutralizingPeptide FragmentsProtein EngineeringSingle-Domain AntibodiesAlzheimer DiseaseAnimalsHumansProtein MultimerizationAmyloid beta-PeptidesAntibodies, NeutralizingPeptide FragmentsSingle-Domain Antibodies

Identifiers

PMID41896453
PMCPMC13332026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.